Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of CV Sciences with an Overweight rating and $4.20 price target. The analyst noted that CV Sciences owns one of the leading brands in the fast-growing CBD industry in PlusCBD Oil, and believes that as larger retailers start stocking CBD, the more established brands, like CV Science's, will benefit due to supply chain. Zuanic cited valuation, the company's #2 place in the marketplace, positive EBITDA, and lower expectations against peers as reasons to recommend it for investors looking for U.S. CBD industry exposure.